Patricia Galván

6.5k total citations · 2 hit papers
69 papers, 2.4k citations indexed

About

Patricia Galván is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Patricia Galván has authored 69 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 40 papers in Pulmonary and Respiratory Medicine and 38 papers in Cancer Research. Recurrent topics in Patricia Galván's work include Advanced Breast Cancer Therapies (29 papers), Breast Cancer Treatment Studies (29 papers) and HER2/EGFR in Cancer Research (27 papers). Patricia Galván is often cited by papers focused on Advanced Breast Cancer Therapies (29 papers), Breast Cancer Treatment Studies (29 papers) and HER2/EGFR in Cancer Research (27 papers). Patricia Galván collaborates with scholars based in Spain, United States and Italy. Patricia Galván's co-authors include Aleix Prat, Montserrat Muñoz-Mateu, Bárbara Adamo, Lydia Gaba, Ana Arance, Aranzazu Fernández-Martínez, Estela Pineda, Marc Díez, Margarita Viladot and Laia Paré and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Patricia Galván

59 papers receiving 2.4k citations

Hit Papers

Clinical implications of the intrinsic molecular subtypes... 2015 2026 2018 2022 2015 2020 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical implications of the intrinsic molecular subtypes of breast cancer
    2015 751 citations Aleix Prat, Estela Pineda et al. The Breast profile →
  2. Frequency and spectrum of PIK3CA somatic mutations in breast cancer
    2020 227 citations Olga Martínez‐Sáez, Núria Chic et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patricia Galván Spain 20 1.4k 997 947 671 263 69 2.4k
Marco Gerlinger United Kingdom 22 955 0.7× 1.2k 1.2× 1.1k 1.1× 647 1.0× 162 0.6× 62 2.4k
Mónica V. Estrada United States 16 1.4k 1.0× 925 0.9× 1.3k 1.3× 677 1.0× 112 0.4× 25 2.5k
Laia Paré Spain 25 1.5k 1.1× 936 0.9× 848 0.9× 716 1.1× 232 0.9× 98 2.5k
Daniel Nava Rodrigues United Kingdom 26 878 0.6× 820 0.8× 948 1.0× 1.0k 1.5× 177 0.7× 54 2.2k
Pradip De United States 22 988 0.7× 596 0.6× 1.0k 1.1× 438 0.7× 170 0.6× 36 2.0k
Anne‐Vibeke Lænkholm Denmark 30 1.2k 0.9× 1.2k 1.2× 1.2k 1.2× 461 0.7× 302 1.1× 120 2.6k
Coya Tapia Switzerland 28 1.1k 0.8× 752 0.8× 838 0.9× 461 0.7× 239 0.9× 47 2.3k
Mohammed A. Aleskandarany United Kingdom 36 1.6k 1.2× 1.5k 1.5× 1.7k 1.8× 510 0.8× 222 0.8× 81 3.4k
Elin Borgen Norway 31 2.3k 1.7× 1.8k 1.8× 950 1.0× 756 1.1× 178 0.7× 88 3.3k
Matthias Christgen Germany 28 1.3k 0.9× 1.2k 1.2× 1.1k 1.2× 352 0.5× 222 0.8× 113 2.5k

Countries citing papers authored by Patricia Galván

Since Specialization
Citations

This map shows the geographic impact of Patricia Galván's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia Galván with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia Galván more than expected).

Fields of papers citing papers by Patricia Galván

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia Galván. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia Galván. The network helps show where Patricia Galván may publish in the future.

Co-authorship network of co-authors of Patricia Galván

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia Galván. A scholar is included among the top collaborators of Patricia Galván based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia Galván. Patricia Galván is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pernas, Sònia, Esther Sanfeliu, Guillermo Villacampa, et al.. (2024). Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy. npj Breast Cancer. 10(1). 101–101.
2.
Schettini, Francesco, Michela Palleschi, Fara Brasó‐Maristany, et al.. (2024). CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. The Oncologist. 29(5). e622–e634. 4 indexed citations
3.
Llombart‐Cussac, Antonio, Fara Brasó‐Maristany, Laia Paré, et al.. (2024). HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial. Clinical Cancer Research. 30(18). 4123–4130. 5 indexed citations
4.
Pascual, Tomás, Juan Miguel Cejalvo, Mafalda Oliveira, et al.. (2023). 387MO First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer. Annals of Oncology. 34. S341–S342. 1 indexed citations
5.
Martínez‐Sáez, Olga, Fara Brasó‐Maristany, Mercedes Marín‐Aguilera, et al.. (2023). 8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer. ESMO Open. 8(1). 101232–101232.
6.
7.
Quintana, Ángela, Vicente Peg, Aleix Prat, et al.. (2021). Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. European Journal of Cancer. 148. 134–145. 12 indexed citations
8.
Pascual, Tomás, Mafalda Oliveira, Patricia Villagrasa, et al.. (2021). Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. npj Breast Cancer. 7(1). 145–145. 8 indexed citations
9.
Prat, Aleix, Yi‐Hsuan Tsai, Tomás Pascual, et al.. (2020). A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer. Clinical Cancer Research. 26(23). 6141–6148. 5 indexed citations
10.
Martínez‐Sáez, Olga, Tomás Pascual, Fara Brasó‐Maristany, et al.. (2020). 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i). Annals of Oncology. 31. S17–S17.
11.
González‐Farré, Blanca, Paolo Nucíforo, Javier Cortés, et al.. (2020). 15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): A SOLTI biomarker analysis. Annals of Oncology. 31. S22–S22.
12.
13.
Griguolo, Gaia, Garazi Serna, Tomás Pascual, et al.. (2020). 8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT). Annals of Oncology. 31. S19–S19. 1 indexed citations
14.
Gunawardana, Manjula, Simon G. Webster, Patricia Galván, et al.. (2020). Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis. Frontiers in Pharmacology. 11. 569373–569373. 19 indexed citations
15.
Prat, Aleix, Alejandro Navarro, Laia Paré, et al.. (2017). Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research. 77(13). 3540–3550. 277 indexed citations
16.
Prat, Aleix, Patricia Galván, Begoña Jiménez, et al.. (2015). Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clinical Cancer Research. 22(3). 560–566. 64 indexed citations
17.
Prat, Aleix, Estela Pineda, Bárbara Adamo, et al.. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast. 24. S26–S35. 751 indexed citations breakdown →
18.
Montemurro, Filippo, Aleix Prat, Valentina Rossi, et al.. (2013). Potential biomarkers of long‐term benefit from single‐agent trastuzumab or lapatinib in HER2‐positive metastatic breast cancer. Molecular Oncology. 8(1). 20–26. 35 indexed citations
19.
García, Idoia, José Ríos, Gema Doménech, et al.. (2012). A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clinical Cancer Research. 18(7). 2012–2023. 51 indexed citations
20.
Ordóñez, José Luis, Eva Rodríguez, Patricia Galván, et al.. (2012). The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis. Carcinogenesis. 34(2). 268–276. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Gerlinger Breakdown of academic impact, for papers by Mónica V. Estrada Breakdown of academic impact, for papers by Laia Paré Breakdown of academic impact, for papers by Daniel Nava Rodrigues Breakdown of academic impact, for papers by Pradip De Breakdown of academic impact, for papers by Anne‐Vibeke Lænkholm Breakdown of academic impact, for papers by Coya Tapia Breakdown of academic impact, for papers by Mohammed A. Aleskandarany Breakdown of academic impact, for papers by Elin Borgen Breakdown of academic impact, for papers by Matthias Christgen
Rankless by CCL
2026